Tran Ann Q, Choi Catherine J, Wester Sara T
University of Miami - Bascom Palmer Eye Institute, Department of Ophthalmology.
Intern Med Rev (Wash D C). 2016 Oct;2(9). doi: 10.18103/imr.v2i9.221.
Infantile hemangiomas (IH) are the most common benign tumor of infancy, and in the periocular region can be associated with permanent visual impairment from amblyopia. Previous treatment options included systemic and local corticosteroids, surgical excision, laser therapy, and in rare cases immunomodulatory therapy, many of which had variable outcomes with undesirable side effect profiles. Since their initial use for IH in 2008, beta blockers have become the mainstay of therapy for periocular IH due to their excellent clinical efficacy and tolerability. While the exact mechanism of action of beta blockers in IH has not been fully elucidated, both oral and topical therapy have demonstrated low rates of adverse events and improved outcomes in the management of periocular IH. This review summarizes the most recent studies on the clinical outcomes, management, and guidelines for the treatment of periocular IH with topical and oral beta blockers.
婴儿血管瘤(IH)是婴儿期最常见的良性肿瘤,在眼周区域可导致因弱视引起的永久性视力损害。以前的治疗选择包括全身和局部使用皮质类固醇、手术切除、激光治疗,以及在罕见情况下使用免疫调节治疗,其中许多治疗效果不一,且有不良副作用。自2008年首次用于治疗婴儿血管瘤以来,β受体阻滞剂因其出色的临床疗效和耐受性,已成为眼周婴儿血管瘤治疗的主要手段。虽然β受体阻滞剂在婴儿血管瘤中的确切作用机制尚未完全阐明,但口服和局部治疗在眼周婴儿血管瘤的管理中均显示出不良事件发生率低且预后改善。本综述总结了关于局部和口服β受体阻滞剂治疗眼周婴儿血管瘤的临床结果、管理及治疗指南的最新研究。